title: Optic chiasmal herniation--an under recognized complication of dopamine agonist therapy for macroprolactinoma.
abstract: The initial presentation of macroprolactinoma with visual field impairment, especially in males, is well recognized. Successful treatment with dopamine agonist therapy is characterized by a reduction in hyperprolactinaemia and often rapid and progressive resolution of the visual impairment. A small proportion of patients may subsequently develop a secondary deterioration in both their visual fields and visual acuities despite normalization of prolactin levels and tumour shrinkage. When pituitary apoplexy can be excluded this may result from traction on the optic chiasm which is pulled down into the now partially empty sella. We report a series of seven patients in whom chiasmal traction is believed to be the cause of their secondary deterioration in visual acuity occurring after dopamine agonist therapy for macroprolactinoma. The clinical history of two patients both of whom had rapid resolution of field defect with bromocriptine therapy but subsequently developed a recurrence of their bitemporal hemianopia is detailed. In both patients MRI scanning showed not only tumour involution but also marked optic chiasm herniation into the pituitary fossa. Surgical treatment was considered too risky; but on reduction of bromocriptine dosage the field defect improved in both cases; there was a modest elevation of prolactin and a degree of tumour re-expansion. The latter is believed to have released tethering of the optic chiasm and/or its vascular supply and thus obviated the need for surgery. Regular monitoring of visual fields in patients with macroprolactinoma receiving medical treatment is therefore important. Early recognition of secondary field loss due to chiasmal herniation enables correction of the visual field loss by manipulation of the medical therapy.
authors.affiliation: Department of Endocrinology, Radiology, Royal Victoria Infirmary, Newcastle upon Tyne, UK. susan.jones@ncl.ac.uk
authors.forename: S E
authors.initials: SE
authors.lastname: Jones
authors.forename: R A
authors.initials: RA
authors.lastname: James
authors.forename: K
authors.initials: K
authors.lastname: Hall
authors.forename: P
authors.initials: P
authors.lastname: Kendall-Taylor
mesh_terms: D000328:Adult; D001971:Bromocriptine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006547:Hernia; D006801:Humans; D008297:Male; D008875:Middle Aged; D009897:Optic Chiasm; D010911:Pituitary Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D014786:Vision Disorders / Q000139:chemically induced*; D014792:Visual Acuity
chemical_list: D018491:Dopamine Agonists; D001971:Bromocriptine; D011388:Prolactin